开云app官网登录入口网页版-官方正版

#Veliparib#

17篇内容 | 1162人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361247, encodeId=6644136124e06, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=58, createdTime=2022-02-17, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361246, encodeId=91ef136124601, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=80, createdTime=2022-02-04, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361245, encodeId=506a1361245ca, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=103, createdTime=2021-12-11, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361244, encodeId=d40b13612448b, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, objectType=article, longId=216406, objectId=13bc21640686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bc21640686, replyNumber=0, likeNumber=63, createdTime=2021-08-29, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bc21640686, moduleTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=13bc21640686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361243, encodeId=523d136124306, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, objectType=article, longId=214609, objectId=4c4421460961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c4421460961, replyNumber=0, likeNumber=97, createdTime=2021-07-23, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c4421460961, moduleTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4c4421460961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361242, encodeId=5e15136124223, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, objectType=article, longId=200007, objectId=6f2b20000e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2b20000e60, replyNumber=0, likeNumber=67, createdTime=2020-08-30, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2b20000e60, moduleTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6f2b20000e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361241, encodeId=d658136124174, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, objectType=article, longId=197253, objectId=32b119e253bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b119e253bc, replyNumber=0, likeNumber=58, createdTime=2020-07-10, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b119e253bc, moduleTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=32b119e253bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361240, encodeId=db541361240cf, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, objectType=article, longId=190106, objectId=ce37190106a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce37190106a8, replyNumber=0, likeNumber=58, createdTime=2020-03-18, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce37190106a8, moduleTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ce37190106a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361239, encodeId=3333136123966, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌, objectType=article, longId=184965, objectId=4d61184965a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d61184965a6, replyNumber=0, likeNumber=0, createdTime=2019-12-21, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d61184965a6, moduleTitle=NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4d61184965a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361238, encodeId=f19f136123809, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤, objectType=article, longId=159009, objectId=1690159009ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1690159009ef, replyNumber=0, likeNumber=71, createdTime=2019-01-28, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1690159009ef, moduleTitle=CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1690159009ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361237, encodeId=2671136123e4b, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？, objectType=article, longId=157547, objectId=091815e54770, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091815e54770, replyNumber=0, likeNumber=64, createdTime=2019-01-09, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091815e54770, moduleTitle=JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=091815e54770)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361236, encodeId=9ab3136123604, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, objectType=article, longId=131089, objectId=56eb131089ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56eb131089ae, replyNumber=0, likeNumber=63, createdTime=2018-03-03, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56eb131089ae, moduleTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=56eb131089ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=CLIN CANCER RES：Veliparib联合托泊替康治疗实体肿瘤, objectType=article, longId=130697, objectId=aaf713069e04, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaf713069e04, replyNumber=0, likeNumber=62, createdTime=2018-02-28, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaf713069e04, moduleTitle=CLIN CANCER RES：Veliparib联合托泊替康治疗实体肿瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=aaf713069e04)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361234, encodeId=3a3113612342f, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=75, createdTime=2017-12-28, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361233, encodeId=4d3313612335e, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, objectType=article, longId=93776, objectId=2b1b93e7645, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1b93e7645, replyNumber=0, likeNumber=62, createdTime=2017-03-30, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1b93e7645, moduleTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2b1b93e7645)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361232, encodeId=f7ae1361232ce, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定, objectType=article, longId=82037, objectId=85118203ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85118203ef1, replyNumber=0, likeNumber=69, createdTime=2016-11-11, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85118203ef1, moduleTitle=喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=85118203ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361231, encodeId=72e213612318a, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, objectTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, objectType=article, longId=72400, objectId=4e9ce240078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9ce240078, replyNumber=0, likeNumber=70, createdTime=2016-07-10, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9ce240078, moduleTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4e9ce240078)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Veliparib

2020-05-29

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-02-17

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-02-04

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2021-12-11

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果

2021-08-29

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性

2021-07-23

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效

2020-08-30

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究

2020-07-10

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后

2020-03-18

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌

2019-12-21

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤

2019-01-28

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？

2019-01-09

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响

2018-03-03

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

CLIN CANCER RES：Veliparib联合托泊替康治疗实体肿瘤

2018-02-28

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2017-12-28

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性

2017-03-30

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定

2016-11-11

jiangfeng5067 (审核中...)

前往app查看评论内容

#Veliparib#

NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好

2016-07-10

科室
- - 订阅+
  - 更多科室
工具
服务